AUTL

In a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Autolus Therapeutics (AUTL - Research Report), with a price target of $18.00. The company's shares opened today at $1.89.Goldstein covers the Healthcare sector, focusing on stocks such as Incyte, Arcus Biosciences, and Autolus Therapeutics. According to TipRanks, Goldstein has an average return of 1.8% and a 37.07% success rate on recommended stocks. Autolus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $11.00, a 482.01% upside from current levels. In a report released on December 9, Needham also reiterated a Buy rating on the stock with a $7.00 price target.
https://www.tipranks.com/news/blurbs/mizuho-securities-remains-a-buy-on-autolus-therapeutics-autl?utm_source=advfn.com&utm_medium=referral